psoralidin是一种从补骨脂(Psoralea corylifolia L.)中分离出的天然呋喃香豆素,具有抗癌和化学预防特性,能够抑制Akt磷酸化和磷脂酰肌醇3-激酶的激活。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | Akt ↓ ↑ | Akt1 ↓ ↑ | Akt2 ↓ ↑ | Akt3 ↓ ↑ | 其他靶点 | 纯度 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Honokiol | ✔ | MEK | 98% | ||||||||||||||||
| PF-04691502 |
++++
P-Akt (S473), IC50: 3.8 nM P-Akt (T308), IC50: 7.5 nM |
98+% | |||||||||||||||||
| PHT-427 |
+
Akt, Ki: 2.7 μM |
99%+ | |||||||||||||||||
| Deguelin | ✔ | PI3K | 99%+ | ||||||||||||||||
| TIC10 isomer | ✔ | ERK | 98+% | ||||||||||||||||
| Perifosine |
+
Akt, IC50: 4.7 μM |
98% | |||||||||||||||||
| Miltefosine | ✔ | PKC,PI3K | 98% | ||||||||||||||||
| Triciribine |
+
Akt, IC50: 130 nM |
99%+ | |||||||||||||||||
| Uprosertib |
+
Akt1, IC50: 180 nM |
+
Akt2, IC50: 328 nM |
++
Akt3, IC50: 38 nM |
99%+ | |||||||||||||||
| Afuresertib |
++++
Akt1, Ki: 0.08 nM |
++++
Akt2, Ki: 2 nM |
++++
Akt3, Ki: 2.6 nM |
99%+ | |||||||||||||||
| Miransertib |
++++
Akt1, IC50: 5 nM |
++++
Akt2, IC50: 4.5 nM |
++
Akt3, IC50: 16 nM |
98+% | |||||||||||||||
| GSK-690693 |
++++
Akt1, IC50: 2 nM |
+++
Akt2, IC50: 13 nM |
+++
Akt3, IC50: 9 nM |
99%+ | |||||||||||||||
| AT7867 |
++
Akt1, IC50: 32 nM |
++
Akt2, IC50: 17 nM |
++
Akt3, IC50: 47 nM |
PKA | 99%+ | ||||||||||||||
| AKT inhibitor VIII |
++
Akt1, IC50: 58 nM |
+
Akt2, IC50: 210 nM |
+
Akt3, IC50: 2119 nM |
97% | |||||||||||||||
| MK-2206 2HCl |
+++
Akt1, IC50: 8 nM |
+++
Akt2, IC50: 12 nM |
+
Akt3, IC50: 65 nM |
99%+ | |||||||||||||||
| Ipatasertib |
++++
Akt1, IC50: 5 nM |
++
Akt2, IC50: 18 nM |
+++
Akt3, IC50: 8 nM |
99%+ | |||||||||||||||
| AT13148 |
++
Akt1, IC50: 38 nM |
+
Akt2, IC50: 402 nM |
++
Akt3, IC50: 50 nM |
PKA | 95% | ||||||||||||||
| Capivasertib |
++++
Akt1, IC50: 3 nM |
+++
Akt2, IC50: 8 nM |
+++
Akt3, IC50: 8 nM |
99%+ | |||||||||||||||
| A-674563 HCl |
+++
Akt1, Ki: 11 nM |
PKA | 99% | ||||||||||||||||
| CCT128930 |
+++
Akt2, IC50: 6 nM |
PKA | 95% | ||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 描述 | Psoralidin is a dual inhibitor of COX-2 and 5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation, with anti-cancer, anti-bacterial, and anti-inflammatory properties[3]. Three breast cancer cell populations (ALDH- cells, ALDH+ cells, and commercial BSCSs) are sensitive to Psoralidin treatment (10, 15, 20, and 25 μM; 24 hours) with IC50s ranging from 18 to 21 μM; however, the MCF-12A cells were resistant to Psoralidin. Psoralidin (30 μM; 24 hours) results in a significant induction of apoptosis for ALDH- cells, ALDH+ cells, and commercial BCSCs[4]. Psoralidin decreased the viability of the liver cancer HepG2 cells and exhibited an IC50 of 9 µM. Also, Psoralidin exerted very low toxic effects on the normal AML12 hepatocytes exhibiting an IC50 of 100 µM[5]. Psoralidin treatment could reverse the caffeine-induced dysfunctions and aberrant differentiation of BMSCs (bone marrow mesenchymal stem cells) via the ER pathway[6]. |
| Concentration | Treated Time | Description | References | |
| PC-3 cells | 60 µM | 24 hours | Psoralidin inhibited viability and induced apoptosis in PC-3 cells | Apoptosis. 2010 Feb;15(2):153-61 |
| HL-1 cardiomyocytes | 10, 20, 50, 100 µM | 24 hours | Evaluate the toxic effects of psoralidin on HL-1 cardiomyocytes, showing no significant toxicity at concentrations ≤50 μM. | J Adv Res. 2022 Sep;40:249-261 |
| Commercial breast cancer stem cells (BCSCs) | 10, 15, 20, 25 µM | 24 hours | To evaluate the effect of psoralidin on cell viability, results showed that psoralidin significantly inhibited the growth of BCSCs with IC50 values ranging from 18-21 μM | Br J Cancer. 2013 Nov 12;109(10):2587-96 |
| MDA-MB-231 cells (ALDH+) | 10, 15, 20, 25 µM | 24 hours | To evaluate the effect of psoralidin on cell viability, results showed that psoralidin significantly inhibited the growth of ALDH+ cells with IC50 values ranging from 18-21 μM | Br J Cancer. 2013 Nov 12;109(10):2587-96 |
| MDA-MB-231 cells (ALDH-/C0) | 10, 15, 20, 25 µM | 24 hours | To evaluate the effect of psoralidin on cell viability, results showed that psoralidin significantly inhibited the growth of ALDH-/C0 cells with IC50 values ranging from 18-21 μM | Br J Cancer. 2013 Nov 12;109(10):2587-96 |
| DU-145 cells | 45 µM | 24 hours | Psoralidin inhibited viability and induced apoptosis in DU-145 cells | Apoptosis. 2010 Feb;15(2):153-61 |
| MG63 cells | 0–50 µM | 24 or 48 hours | PSO inhibited OS cell proliferation in a dose-dependent and time-dependent manner. | Chin Med. 2023 Mar 31;18(1):34 |
| 143B cells | 0–50 µM | 24 or 48 hours | PSO inhibited OS cell proliferation in a dose-dependent and time-dependent manner. | Chin Med. 2023 Mar 31;18(1):34 |
| HL-1 cardiomyocytes | 20 µM | 3 hours | Psoralidin pretreatment significantly increased cell viability, reduced apoptosis rate, intracellular ROS generation, and LDH release. | J Adv Res. 2022 Sep;40:249-261 |
| DU-145 cells | 45 µM | 30 and 60 minutes | Psoralidin inhibited both constitutive and epidermal growth factor (EGF)-induced EGFR activation and simultaneously triggered SAPK signaling, resulting in the induction of apoptosis in AIPC cells. | Mol Cancer Ther. 2010 Sep;9(9):2488-96 |
| PC-3 cells | 60 µM | 30 and 60 minutes | Psoralidin inhibited both constitutive and epidermal growth factor (EGF)-induced EGFR activation and simultaneously triggered SAPK signaling, resulting in the induction of apoptosis in AIPC cells. | Mol Cancer Ther. 2010 Sep;9(9):2488-96 |
| Ichthyophthirius multifiliis theronts | 0.8 mg/L or higher | 4 hours | Evaluate the killing effect of psoralidin on I. multifiliis theronts, results showed that at 0.8 mg/L or higher concentrations, all theronts were killed within 4 hours | Int J Parasitol Drugs Drug Resist. 2015 Apr 21;5(2):58-64 |
| Human lung adenocarcinoma cell lines (A549) | 0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30, 100, 300 µg/mL | 48 hours | To evaluate the cytotoxicity of psoralidin and its nanoformulation on A549 cells. Results showed that Ps-CS/BLs had an IC50 value of 3.56 ± 0.36 µg/mL, significantly lower than free psoralidin (48.94 ± 1.3 µg/mL). | Polymers (Basel). 2023 Mar 15;15(6):1464 |
| Human breast cancer cell lines (MCF-7) | 0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30, 100, 300 µg/mL | 48 hours | To evaluate the cytotoxicity of psoralidin and its nanoformulation on MCF-7 cells. Results showed that Ps-CS/BLs had an IC50 value of 1.19 ± 0.24 µg/mL, significantly lower than free psoralidin (39.85 ± 1.1 µg/mL). | Polymers (Basel). 2023 Mar 15;15(6):1464 |
| HeLa cells | 20-50 µM | 48 hours | To evaluate the cytotoxic and apoptotic activities of psoralidin in HeLa cells. Results showed that psoralidin induced apoptosis in a concentration-dependent manner, with 13.5 ± 1.2% apoptosis at 50 μM. | Molecules. 2012 May 29;17(6):6449-64 |
| Administration | Dosage | Frequency | Description | References | ||
| BALB/c mice | ADR-induced cardiotoxicity model | Intraperitoneal injection | 12.5, 25, 50 mg/kg | Every two days, three times in total | Psoralidin significantly increased the survival rate of ADR-injured mice, improved cardiac function indicators, and reduced myocardial fibrosis, oxidative stress, and apoptosis. | J Adv Res. 2022 Sep;40:249-261 |
| Goldfish (Carassius auratus) | I. multifiliis infection model | Water bath administration | 2.5 mg/L | 5 hours | Evaluate the in vivo therapeutic effect of psoralidin on I. multi?liis infected gold?sh, results showed that 2.5 mg/L concentration for 5 hours significantly reduced the number of theronts released | Int J Parasitol Drugs Drug Resist. 2015 Apr 21;5(2):58-64 |
| Balb/c nude mice | CTPE xenograft model | Oral | 20 mg/kg | 5 days per week for 4-5 weeks | Oral administration of Psoralidin significantly suppressed CTPE xenograft growth without observable toxicity. Tumours from Pso-treated animals showed decreased autophagic morphology, mesenchymal markers expression, and increased epithelial protein expression. | Br J Cancer. 2017 Jun 27;117(1):56-64 |
| Balb/c athymic nude mice | ALDH+, CD44+/CD22− and ALDH− xenograft models | Oral | 25 mg/kg | 5 days a week for 4 weeks | Psoralidin significantly inhibited the growth of ALDH+, CD44+/CD22? and ALDH? tumors and inhibited Notch-1 mediated EMT activation. | Mol Carcinog. 2017 Mar;56(3):1127-1136 |
| BALB/c nude mice | Orthotopic osteosarcoma mouse model | Oral gavage | 5, 10, or 20 mg/kg | Every two days for three weeks | PSO significantly inhibited osteosarcoma growth and metastasis. | Chin Med. 2023 Mar 31;18(1):34 |
| Mice | PC-3 xenograft model | Oral | 50 mg/kg | Not specified | Psoralidin inhibited tumor growth and induced apoptosis | Apoptosis. 2010 Feb;15(2):153-61 |
| Nude mice | PC-3 xenograft model | Oral | 50 mg/kg | Five days a week for four weeks | Psoralidin effectively suppressed PC-3 xenograft tumors by inhibiting EGFR-mediated survival signaling with a simultaneous induction of SAPK-mediated apoptotic events. | Mol Cancer Ther. 2010 Sep;9(9):2488-96 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.97mL 0.59mL 0.30mL |
14.87mL 2.97mL 1.49mL |
29.73mL 5.95mL 2.97mL |
|
| CAS号 | 18642-23-4 |
| 分子式 | C20H16O5 |
| 分子量 | 336.34 |
| SMILES Code | O=C1C2=C(OC3=CC(O)=CC=C32)C4=C(O1)C=C(O)C(CC=C(C)C)=C4 |
| MDL No. | MFCD10566617 |
| 别名 | |
| 运输 | 蓝冰 |
| InChI Key | YABIJLLNNFURIJ-UHFFFAOYSA-N |
| Pubchem ID | 5281806 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, inert atmosphere, store in freezer, under -20°C |
| 溶解方案 |
DMSO: 50 mg/mL(148.66 mM),配合低频超声,并水浴加热至45℃助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1